✦ LIBER ✦

Tocilizumab in Polyarticular Juvenile Idiopathic Arthritis – A Cost-Utility Model for the United Kingdom

✍ Scribed by Chang, S.; Sawyer, L.; Dejonckheere, F.; van Suijlekom-Smit, L.W.; Anink, J.; Diamantopoulos, A.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Utility Analysis Of Tocilizumab In

✍ Vicente, C.; Sabapathy, S.; Formica, L.; Maturi, B.; Piwko, C. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Trial of early aggressive therapy in pol

✍ Carol A. Wallace; Edward H. Giannini; Steven J. Spalding; Philip J. Hashkes; Kat 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB

PMS48 Tocilizumab in Methotrexate-Intole

✍ D. Harland; C. Gibbons; A. Diamantopoulos; H. Pang; C. Huertas; F. Dejonckheere 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

A Cost-Utility Analysis of Lighterlife T

✍ Lewis, L.; Taylor, M. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PMH38 A COST UTILITY ANALYSIS OF FIRST L

✍ Jones, MA; Meier, GC 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

A Cost-Utility Analysis of Everolimus Pl

✍ Taylor, M.; Lewis, L.; Vieira, J.; Chandiwana, D. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB